Predictive
Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”)
to personalized medicine and drug discovery, today announced its receipt of
interest from several parties for the possible acquisition of its Skyline
Medical division, which produces and sells the STREAMWAY System for disposal of
fluids in medical applications. Predictive Oncology previously announced
intentions to focus its resources on its primary mission of applying artificial
intelligence to precision medicine and drug discovery. “I am exceptionally pleased
with the rapid growth and development of our Helomics and Tumor Genesis
divisions, as well as the multiple indications of interest for our Skyline
Medical division,” Predictive Oncology CEO Dr. Carl Schwartz said in the news
release. “If this results in the sale of Skyline Medical, it would not only
provide additional working capital, it would also allow Predictive Oncology to
focus on the further development and commercialization of our two divisions
focused on precision medicine.”
To view the full press release, visit http://ibn.fm/yAar1
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five
segments (domestic, international, clinical, CRO and DCHIP), which contain four
subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
Helomics applies artificial intelligence to its rich data gathered from patient
tumors to both personalize cancer therapies for patients and drive the
development of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient-treatment decisions by providing an
evidence-based road map for therapy. In addition to its proprietary
precision-oncology platform, Helomics offers boutique CRO services that
leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range
of multi-omics assays (genomics, proteomics and biochemical) and an AI-powered,
proprietary bioinformatics platform (DCHIP) to provide tailored solutions to
clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is
developing a new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still growing inside a
patient. POAI’s proprietary Oncology Discovery Technology Platform kits will
assist researchers and clinicians in identifying which cancer cells bind to
specific biomarkers. Once the biomarkers are identified, they can be used in
TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help
categorize an individual patient’s heterogeneous tumor samples to enable the
development of patient-specific treatment options. Helomics and TumorGenesis
are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division
markets its patented and FDA-cleared STREAMWAY System, which automates the
collection, measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through both domestic
and international divisions. The company has achieved sales in five of the
seven continents through both direct sales and distributor partners. For more
information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
